A5007202196- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Immune Cell Function and Interaction
- Toxin Mechanisms and Immunotoxins
- Virus-based gene therapy research
- Cytokine Signaling Pathways and Interactions
- Carbon Nanotubes in Composites
- Graphene and Nanomaterials Applications
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Nanoparticle-Based Drug Delivery
- Protein Degradation and Inhibitors
- Mathematical Biology Tumor Growth
- RNA Interference and Gene Delivery
- Single-cell and spatial transcriptomics
- T-cell and B-cell Immunology
- Nanoparticles: synthesis and applications
- Neuroscience and Neuropharmacology Research
- Medicinal Plants and Neuroprotection
- Chemical synthesis and alkaloids
- vaccines and immunoinformatics approaches
Cullinan Oncology (United States)
2022-2024
Stanford University
2009-2021
Massachusetts Institute of Technology
2013-2021
Ragon Institute of MGH, MIT and Harvard
2021
Birla Institute of Technology and Science, Pilani
2004
The evidence is stacking up: Many therapeutic advantages such as prolonged circulation in the blood, increased tumor drug uptake, enhanced efficacy, and markedly reduced toxic side effects are provided by a carbon nanotube based chemotherapeutic formulation (see picture). In this system, doxorubicin (DOX) loaded onto sidewalls of functionalized single-walled nanotubes supramolecular π–π stacking.
Abstract Inorganic nanoparticles (NPs) are studied as drug carriers, radiosensitizers and imaging agents, characterizing nanoparticle biodistribution is essential for evaluating their efficacy safety. Tracking NPs at the single-cell level with current technologies complicated by lack of reliable methods to stably label particles over extended durations in vivo . Here we demonstrate that mass cytometry time-of-flight provides a label-free approach inorganic quantitation cells. Furthermore,...
Tissue-resident memory T cells (TRMs) can profoundly enhance mucosal immunity, but parameters governing TRM induction by vaccination remain poorly understood. Here, we describe an approach exploiting natural albumin transport across the airway epithelium to generation vaccination. Pulmonary immunization with albumin-binding amphiphile conjugates of peptide antigens and CpG adjuvant (amph-vaccines) increased vaccine accumulation in lung mediastinal lymph nodes (MLNs). Amph-vaccines prolonged...
Background Major histocompatibility complex class I-related protein A and B (MICA/B) are ligands for the natural killer group 2 member D (NKG2D) receptor broadly expressed on tumor cells but minimally normal tissues. When cytotoxic NKG2D-expressing immune engage MICA/B, ligand-expressing targeted lysis. Cancer can evade NKG2D-mediated destruction by shedding MICA/B from their cell surface via proteases present in microenvironment. CLN-619 is a humanized IgG1 monoclonal antibody (mAb) which...
The suppression of oncogenic levels MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation in conditional transgenic mouse model Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some the tumors recur, recapitulating what frequently observed human response targeted therapies. Here we report that these recurring...
Abstract Despite clinical evidence of antitumor activity, the development cytokine therapies has been hampered by a narrow therapeutic window and limited response rates. Two cytokines high interest for are interleukin 2 (IL2) 12 (IL12), which potently synergize to promote activation proliferation T cells NK cells. However, only approved human IL2 therapy, Proleukin, is rarely used in clinic due systemic toxicities, no IL12 product date severe dose-limiting toxicities. Here, we describe...
<div>Abstract<p>Despite clinical evidence of antitumor activity, the development cytokine therapies has been hampered by a narrow therapeutic window and limited response rates. Two cytokines high interest for are interleukin 2 (IL2) 12 (IL12), which potently synergize to promote activation proliferation T cells NK cells. However, only approved human IL2 therapy, Proleukin, is rarely used in clinic due systemic toxicities, no IL12 product date severe dose-limiting toxicities....
Understanding the complex dynamics between tumor cells and host immune system will be key to improved therapeutic strategies against cancer. We propose an ODE-based mathematical model of both how they respond inactivation driving oncogene. Our supports experimental results showing that cellular senescence is dependent on CD4+ T helper cells, leading relapse tumors in immunocompromised hosts.
Abstract CLN-619 is a humanized IgG1 monoclonal antibody that targets MICA and MICB (MICA/B) currently in phase 1 clinical development cancer patients (NCT05117476). MICA/B serve as activating signals on target cells for recognition by the NKG2D receptor, which expressed NK subset of T cell populations. expression induced response to stressed conditions, thereby enabling NKG2D-mediated elimination cells. On cells, one many receptors complex network inhibitory receptors, whereby pathway...
<div>Abstract<p>Despite clinical evidence of antitumor activity, the development cytokine therapies has been hampered by a narrow therapeutic window and limited response rates. Two cytokines high interest for are interleukin 2 (IL2) 12 (IL12), which potently synergize to promote activation proliferation T cells NK cells. However, only approved human IL2 therapy, Proleukin, is rarely used in clinic due systemic toxicities, no IL12 product date severe dose-limiting toxicities....
<p>T-cell gating scheme for flow cytometry data analysis</p>
<p>Selection of mCLN-617 component parts</p>